Skip to main content
OpenTrials
Completed

NCT Number: NCT07271199

Eyelash Effect Evaluation for Premium Rejuvenation Eyelash Serum

This study aims to evaluate the efficacy of the Premium Rejuvenation Eyelash Serum on eyelashes and the surrounding periorbital skin. A total of 30 healthy female participants, aged 18 to 60, will be recruited and randomly assigned to two groups to receive either test product or placebo at 1:1 ratio. Participants will apply the product twice daily for 56 days (8 weeks), with eyelash and periorbital skin conditions assessed at multiple time points using non-invasive measurements. Key parameters include eyelash density, eyelash length, and overall periorbital skin condition. At the end of the study (Day 56), participant will be asked to fill out a questionnaire on the usage of the intervention and self evaluation of eyelash condition.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Hungkuang University

Taichung, 433304, Taiwan

About this study

This prospective, randomized, double-blinded, placebo-controlled study aims to investigate the effects of Premium Rejuvenation Eyelash Serum on eyelashes and surrounding periorbital skin. A total of 30 healthy female adults aged 18 to 60 will be enrolled. Inclusion criteria require participants to be free from chronic diseases, major illnesses (including cancer, stroke-related disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, or major organ/hematopoietic stem cell transplants), and allergic constitutions. Exclusion criteria include current use of medications or eyelash care products.

Participants will be randomly assigned into two groups of 15 each: Group 1 uses placebo (Base formula without active ingredient); Group 2 uses the experimental formula with ginger (Zingiber officinale)-derived extracellular vesicle + turmeric (Curcuma longa)-derived extracellular vesicles + IGF-1 + FGF-7. Baseline assessments will be conducted prior to product use. Follow-up assessments will occur at Days 28 (4 weeks) and 56 (8 weeks). Evaluations will include eyelash density, change in eyelash length, self-reported periorbital skin condition (e.g., swelling, irritation, pigmentation, redness, and allergic reactions), and a questionnaire. Eyelash parameters will be objectively measured using the Canfield Scientific VISIA® Skin Analysis System. At the conclusion of the study (Day 56), participant self-assessments on the intervention and eyelash condition will be evaluated through a questionnaire.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy female adults from the age of 18 to 60 years (inclusive).
  • Having symptoms of alopecia, baldness, or self-identified with hair thinning.
  • Absence of chronic diseases, major illnesses, or allergies.
  • Major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant

Exclusion criteria

  • Currently taking any medication or using any eyelash care products.

Treatment and study plan

Placebo control

Other

Placebo Control (Base Formula without active ingredients). After thoroughly cleansing the face and removing contact lenses (if applicable), apply 1 mL of the serum evenly to the base of the eyelashes. Allow the serum to absorb for a few minutes. Repeat application twice daily, in the morning and evening.

Experimental formula

Other

Base formula with ginger (Zingiber officinale)-derived extracellular vesicle, turmeric (Curcuma longa)-derived extracellular vesicles, insulin growth factor-1 (IGF-1), and fibroblast growth factor-7 (FGF-7).

After thoroughly cleansing the face and removing contact lenses (if applicable), apply 1 mL of the serum evenly to the base of the eyelashes. Allow the serum to absorb for a few minutes. Repeat this application twice daily, in the morning and evening.

Primary outcomes

  1. Eyelash density

    Time frame: Assessment conducted every 28 days from Day 0 to Day 56 (including Day 0 as baseline)

    Assess eyelash density with Canfield VISIA® Skin Analysis system by assigning score from 1 (most dense, thick eyelashes) to 5 (least dense, thin eyelashes). Results will be expressed as percentage of change in eyelash density percentage relative to Day 0.

  2. Eyelash length

    Time frame: Assessment conducted every 28 days from Day 0 to Day 56 (including Day 0 as baseline)

    Assess eyelash length with Canfield VISIA® Skin Analysis system by assigning score from 1 (longest eyelashes) to 5 (shortest eyelashes). Results will be expressed as percentage of change in eyelash length percentage relative to Day 0

Secondary outcomes

  1. Participant self-assessment

    Time frame: Day 56 (End of the study period)

    Participants will be asked to fill out an assessment form with score from 0 to 5 for each of the eyelash condition and product feedback evaluated.

Sponsors and collaborators

Lead sponsor

Hungkuang University

Other

Collaborators

  • Schweitzer Biotech Company

Registry information

Official study title

Evaluation of the Eyelash Care Effects of Premium Rejuvenation Eyelash Serum

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 9, 2025
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.